Skip to main content
Fig. 3 | Pilot and Feasibility Studies

Fig. 3

From: Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19

Fig. 3

Hematologic parameters. WBC count per microliter in control (A) and intervention (B) groups. Lymphocyte count per microliter in control (C) and intervention (D) groups. The amount of MCV in control (E) and intervention (F) groups. the serumic level of hemoglobin in control (G) and intervention (H) groups. The number of platelet in control (I) and intervention (J) groups. INR ration in control (K) and intervention (L) groups. The amount of D-Dimer in control (M) and intervention (N) groups. The percentage of hematocrit in control (O) and intervention (P) groups’ patients

Back to article page

Pilot and Feasibility Studies

ISSN: 2055-5784